The collaboration has allowed ArsenalBio to develop a robust manufacturing process for their next-generation, programmable autologous T cells to treat cancer.
Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
Adds capabilities and technologies for the development and manufacture of autologous and allogeneic cell therapies, as well as related analytical services